A Phase I Sequential Ascending Dose Trial of AP23573 in Patients With Progressive or Recurrent Malignant Glioma.
Phase of Trial: Phase I
Latest Information Update: 06 May 2014
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors ARIAD Pharmaceuticals; Merck & Co
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2010 Merck and Co added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov record.
- 07 Nov 2008 Updated from ClinicalTrials.gov record.